Elizabeth M. Krantz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elizabeth M. Krantz has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Liu
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
2 shared publications Corey Casper
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
2 shared publications- Emily A. Rosen
Fred Hutchinson Cancer Center
2 shared publications Fred Okuku
Uganda Cancer Institute , Kampala
2 shared publicationsInnocent Mutyaba
Uganda Cancer Institute , Kampala
2 shared publicationsJackson Orem
Uganda Cancer Institute , Kampala
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
An Observational Study of Vaginal Antibacterial Activity and Outcomes After Antibiotic Prescription for Bacterial Vaginosis
Background: Bacterial vaginosis (BV) is the most common cause of vaginal discharge syndrome and is usually treated with metronidazole. BV frequently recurs. Published studies have not linked measured vaginal antibiotic activity (VAA) or antibiotic concentrations to clinical or microbiological BV outcomes. The objective was to determine if VAA in vaginal fluid after diagnosis of BV is associated with persistent/recurrent BV or changes in concentrations of vaginal BV-associated bacteria (BVAB). Methods: VAA was assessed using a bioassay to measure inhibition of growth of BVAB in culture. Persistent/recurrent BV was measured by Amsel clinical criteria at days 6–35 (early) and 36–100 (late), concentrations of indicator BVAB in the vagina by quantitative polymerase chain reaction (PCR), and condom use by questionnaire. Results: Eighty-seven participants who experienced 130 episodes of BV were prescribed metronidazole. No VAA was detected in 40 of 130 (31%) episodes of BV in the 10 days postdiagnosis. VAA was linked to significantly greater declines in vaginal concentrations of indicator BVAB (P < .001). Persistent/recurrent BV was present in 38 of 129 (29%) episodes at days 6–35, and 45 of 63 (71%) episodes at days 36–100. In a multivariable model, VAA on the majority of prescribed days was associated with a reduced risk for recurrent BV at days 6–35 in the absence of condomless sex (relative risk, 0.31; 95% CI, .11–.89; P = .03), but not when condomless sex was reported (P = .49). No associations between VAA and BV recurrence at days 36–100 were found. Conclusions: The combination of metronidazole detection on the majority of prescribed days and condom use is associated with reduced risk of BV recurrence.
- 18 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessAn Observational Study of Vaginal Antibacterial Activity and Outcomes After Antibiotic Prescription for Bacterial Vaginosis
Background: Bacterial vaginosis (BV) is the most common cause of vaginal discharge syndrome and is usually treated with metronidazole. BV frequently recurs. Published studies have not linked measured vaginal antibiotic activity (VAA) or antibiotic concentrations to clinical or microbiological BV outcomes. The objective was to determine if VAA in vaginal fluid after diagnosis of BV is associated with persistent/recurrent BV or changes in concentrations of vaginal BV-associated bacteria (BVAB). Methods: VAA was assessed using a bioassay to measure inhibition of growth of BVAB in culture. Persistent/recurrent BV was measured by Amsel clinical criteria at days 6–35 (early) and 36–100 (late), concentrations of indicator BVAB in the vagina by quantitative polymerase chain reaction (PCR), and condom use by questionnaire. Results: Eighty-seven participants who experienced 130 episodes of BV were prescribed metronidazole. No VAA was detected in 40 of 130 (31%) episodes of BV in the 10 days postdiagnosis. VAA was linked to significantly greater declines in vaginal concentrations of indicator BVAB (P < .001). Persistent/recurrent BV was present in 38 of 129 (29%) episodes at days 6–35, and 45 of 63 (71%) episodes at days 36–100. In a multivariable model, VAA on the majority of prescribed days was associated with a reduced risk for recurrent BV at days 6–35 in the absence of condomless sex (relative risk, 0.31; 95% CI, .11–.89; P = .03), but not when condomless sex was reported (P = .49). No associations between VAA and BV recurrence at days 36–100 were found. Conclusions: The combination of metronidazole detection on the majority of prescribed days and condom use is associated with reduced risk of BV recurrence.
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Open AccessDiagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- Open Access
- 23 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae548
Highly Heterogeneous Kaposi Sarcoma–Associated Herpesvirus Oral Shedding Kinetics Among People With and Without Kaposi Sarcoma and Human Immunodeficiency Virus Coinfection
An improved understanding of oral Kaposi sarcoma–associated herpesvirus (KSHV) viral dynamics could provide insights into transmission risk and guide vaccine development. We evaluated KSHV oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and human immunodeficiency virus (HIV) status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify KSHV using polymerase chain reaction. Shedding rates were defined by number of days with KSHV DNA detected divided by total days with swabs and compared by group using hurdle models. Two hundred ninety-five participants were enrolled; median age was 35 years (range, 18–71 years), and 134 (45%) were male. KSHV was detected more frequently among participants with KS (HIV positive [HIV+]/KS+, 56/76 [74%]; HIV negative [HIV−]/KS+, 9/18 [50%]) than those without KS (HIV+/KS−, 36/125 [29%]; HIV−/KS−, 16/76 [21%]); odds of shedding did not differ significantly by HIV status. Among participants with KSHV detected, shedding rates did not differ significantly by group. Median per-participant viral loads among positive samples were lowest in HIV+/KS+ (3.1 log10 copies/mL) and HIV−/KS+ (3.3 log10 copies/mL) participants relative to HIV+/KS− (3.8 log10 copies/mL) and HIV−/KS− (4.0 log10 copies/mL) participants. All groups had participants with low viral load intermittent shedding and participants with high viral load persistent shedding. Within each group, individual KSHV shedding rate positively correlated with median KSHV log10 copies/mL, and episode duration positively correlated with peak viral load. Oral KSHV shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.
- 23 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae548
Open AccessHighly Heterogeneous Kaposi Sarcoma–Associated Herpesvirus Oral Shedding Kinetics Among People With and Without Kaposi Sarcoma and Human Immunodeficiency Virus Coinfection
An improved understanding of oral Kaposi sarcoma–associated herpesvirus (KSHV) viral dynamics could provide insights into transmission risk and guide vaccine development. We evaluated KSHV oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and human immunodeficiency virus (HIV) status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify KSHV using polymerase chain reaction. Shedding rates were defined by number of days with KSHV DNA detected divided by total days with swabs and compared by group using hurdle models. Two hundred ninety-five participants were enrolled; median age was 35 years (range, 18–71 years), and 134 (45%) were male. KSHV was detected more frequently among participants with KS (HIV positive [HIV+]/KS+, 56/76 [74%]; HIV negative [HIV−]/KS+, 9/18 [50%]) than those without KS (HIV+/KS−, 36/125 [29%]; HIV−/KS−, 16/76 [21%]); odds of shedding did not differ significantly by HIV status. Among participants with KSHV detected, shedding rates did not differ significantly by group. Median per-participant viral loads among positive samples were lowest in HIV+/KS+ (3.1 log10 copies/mL) and HIV−/KS+ (3.3 log10 copies/mL) participants relative to HIV+/KS− (3.8 log10 copies/mL) and HIV−/KS− (4.0 log10 copies/mL) participants. All groups had participants with low viral load intermittent shedding and participants with high viral load persistent shedding. Within each group, individual KSHV shedding rate positively correlated with median KSHV log10 copies/mL, and episode duration positively correlated with peak viral load. Oral KSHV shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.
- Open Access
- 23 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (11) , 1108.e1-1108.e11
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics
- 23 August 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (11) , 1108.e1-1108.e11
Open AccessCOVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics
- Open Access
Highly heterogeneous human herpes virus-8 oral shedding kinetics among people with and without Kaposi sarcoma and HIV- co-infection
Background: An improved understanding of oral human herpesvirus-8 (HHV-8) viral dynamics could provide insights into transmission risk and guide vaccine development. Methods: We evaluated HHV-8 oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and HIV status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify HHV-8 using Polymerase Chain Reaction. Shedding rates were defined by the number of days with HHV-8 detected divided by the total days with swabs and compared by group using hurdle models. Results: 295 participants were enrolled; median age was 35 years (range 18-71), 134 (45%) were male. HHV-8 was detected more frequently among participants with KS (HIV+/KS+ 56/76, 74%; HIV-/KS+ 9/18, 50%) than those without KS (HIV+/KS-36/125, 29%; HIV-/KS-16/76, 21%); odds of shedding did not differ significantly by HIV status. Among participants with HHV-8 detected, shedding rates did not differ significantly by group. Median per-participant viral loads among positive samples were lowest in HIV+/KS+ (3.1 log 10 copies/mL) and HIV-/KS+ participants (3.3 log 10 copies/mL) relative to HIV+/KS-(3.8 log 10 copies/mL) and HIV-/KS-participants (4.0 log 10 copies/mL). All groups had participants with low-viral load intermittent shedding and those with high-viral load persistent shedding. Within each group, individual HHV-8 shedding rate positively correlated with median HHV-8 log 10 copies/mL, and episode duration positively correlated with peak viral load. Conclusions: Oral HHV-8 shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.
Open AccessHighly heterogeneous human herpes virus-8 oral shedding kinetics among people with and without Kaposi sarcoma and HIV- co-infection
Background: An improved understanding of oral human herpesvirus-8 (HHV-8) viral dynamics could provide insights into transmission risk and guide vaccine development. Methods: We evaluated HHV-8 oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and HIV status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify HHV-8 using Polymerase Chain Reaction. Shedding rates were defined by the number of days with HHV-8 detected divided by the total days with swabs and compared by group using hurdle models. Results: 295 participants were enrolled; median age was 35 years (range 18-71), 134 (45%) were male. HHV-8 was detected more frequently among participants with KS (HIV+/KS+ 56/76, 74%; HIV-/KS+ 9/18, 50%) than those without KS (HIV+/KS-36/125, 29%; HIV-/KS-16/76, 21%); odds of shedding did not differ significantly by HIV status. Among participants with HHV-8 detected, shedding rates did not differ significantly by group. Median per-participant viral loads among positive samples were lowest in HIV+/KS+ (3.1 log 10 copies/mL) and HIV-/KS+ participants (3.3 log 10 copies/mL) relative to HIV+/KS-(3.8 log 10 copies/mL) and HIV-/KS-participants (4.0 log 10 copies/mL). All groups had participants with low-viral load intermittent shedding and those with high-viral load persistent shedding. Within each group, individual HHV-8 shedding rate positively correlated with median HHV-8 log 10 copies/mL, and episode duration positively correlated with peak viral load. Conclusions: Oral HHV-8 shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.